CAMF.NS
Latest Trade
59.80INRChange
0.65(+1.10%)Volume
164,084Today's Range
-
61.1052 Week Range
-
71.20As of on the National Stock Exchange of India ∙ Minimum 15 minute delay
Previous Close | 59.15 |
|---|---|
Open | 59.10 |
Volume | 164,084 |
3M AVG Volume | 3.12 |
Today's High | 61.10 |
Today's Low | 59.00 |
52 Week High | 71.20 |
52 Week Low | 38.70 |
Shares Out (MIL) | 121.25 |
Market Cap (MIL) | 7,172.17 |
Forward P/E | 18.48 |
Dividend (Yield %) | -- |
India's Camlin Fine Sciences Sept Quarter Consol Profit Rises
India's Camlin Fine Sciences Reports Profit In June Quarter
Camlin Fine Sciences Says CFCL Mauritius Reverse Merged With CFS Europe S.P.A, Italy
Camlin Fine Sciences Limited is engaged in fine chemicals business. The Company is a provider of antioxidants and shelf life extensions, aroma ingredients, performance chemical products and related solutions for food, animal nutrition, pet food, pharmaceutical and petrochemical industries across the world. Its products include BHA and TBHQ. The Company's offerings in shelf life solutions include XTENDRA, NASURE, REDOX, ENERSUPRA, RENDEROX, POLIACID and BIACID. It produces Catechol, the ingredient used to make Vanillin and Ethyl-Vanillin, that is used in a range of applications, such as bakery products, confectioneries, chocolates, supplements, milk, sweets, custard powder, masala incense stick, scented incense stick, pharma syrups, animal nutrition, chew tablets and laboratory chemicals. Its performance chemicals business is involved in providing specialty chemicals, including Guaiacol, Veratrole, TBC, MEHQ, ODEB, CME, 4-MAP, Hydroquinone and Catechol.
Industry
Chemical Manufacturing
Contact Info
Plot No F/11 & F/12,Wicel Compound
Opp Seepz Main Gate, Midc Central Road
+91.22.67001000
https://www.camlinfs.com/Executive Leadership
Dilip D. Dandekar
Non-Executive Chairman of the Board
Dattatraya R. Puranik
Chief Financial Officer, Executive Director
Ashish S. Dandekar
Managing Director, Executive Director
Arjun Sudhakar Dukane
Executive Director
Anagha S. Dandekar
Additional Non-Executive Director
Price To Earnings (TTM) | 25.81 |
|---|---|
Price To Sales (TTM) | 0.72 |
Price To Book (MRQ) | 1.88 |
Price To Cash Flow (TTM) | 12.19 |
Total Debt To Equity (MRQ) | 137.75 |
LT Debt To Equity (MRQ) | 52.16 |
Return on Investment (TTM) | 5.10 |
Return on Equity (TTM) | 2.65 |
* ENTERED INTO AN JOINT VENTURE AGREEMENT WITH PAHANG PHARMA (S) PTE LTD Source text: http://bit.ly/2Ja1e7P Further company coverage:
* DEC QUARTER CONSOL NET LOSS 103.2 MILLION RUPEES VERSUS LOSS 47.2 MILLION RUPEES YEAR AGO
* SAYS APPROVED ISSUE PRICE OF 92.69 RUPEES PER WARRANT FOR THE PREFERENTIAL ALLOTMENT OF WARRANTS Source text: http://bit.ly/2pQIuEF Further company coverage:
* GETS SHAREHOLDERS' NOD FOR PREFERENTIAL ALLOTMENT OF WARRANTS Source text: http://bit.ly/2pBhQQ0 Further company coverage:
* Says SBI Mutual Fund raises stake in co by 5.9 percent to 7.27 percent
* Says approved issue of 17.2 million shares worth 1.50 billion rupees via QIP Source text : http://bit.ly/2jimV9w Further company coverage:
* Says approved issue price of QIP at 87 rupees per equity share
* Says co entered into preferred supply agreement with Lockheed Martin Advanced Energy Storage
* Sept quarter consol loss 41.5 million rupees versus loss 5.9 million rupees year ago
* June quarter loss after tax 35.5 million rupees versus profit 63.5 million rupees year ago
* Says company has along with its subsidiary cfs europe spa, italy has acquired 51% stake in an entity in china.
* Camlin Fine Sciences - co along with CFS Europe SPA, Italy has acquired 51 percent stake in an entity in China
* Says to consider raising funds not exceeding inr 2.50 billion by way of QIP/GDR/ADR/FCCB/other securities Source text for Eikon: Further company coverage:
* Directed by Maharashtra Pollution Control brd to close manufacturing activities of Tarapur unit for violation of consent conditions
* Dec quarter consol net loss 49.3 million rupees versus profit 26.1 million rupees year ago
* Camlin Fine Sciences clarifies on news item "Fairfax in talks to buy controlling stake in Camlin Fine Sciences."
* Sept quarter consol net loss 8 million rupees versus profit 50.6 million rupees year ago
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.